MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate biosimilarity between test product MabionCD20® and
the reference product - MabThera® (rituximab) and to demonstrate comparative safety and
tolerability of a single course of treatment of MabionCD20® and MabThera® in patients with
moderate to severe active rheumatoid arthritis.